Abstract

Oral Sessions

Day 3, May 17（Fri.）　16:05-16:25　Room B (102)

3B-O2-1605　　PDF

Identification of Biomarkers and Therapeutic Targets of Multiple Sclerosis through MALDI-Imaging Mass Spectrometry at the Proteomics Level

(¹Doshisha Univ., ²Bruker, ³Kyoto Pref. Univ. Med., ⁴Kansai Med. Univ.)
^oNami Tanaka¹, Hiroki Yamashita¹, Takashi Nirasawa², Ryo Kajita², Katsutoshi Taguchi³, Masaki Tanaka³, Takayuki Kondo⁴, Yudai Tsuji¹, Nobuto Kakuda¹, Masaya Ikegawa¹

Multiple sclerosis (MS) is an autoimmune disease; its cardinal symptoms are chronic inflammatory, demyelination and axonal degeneration of central neuro system (CNS). In this study, we applied matrix assisted laser desorption/ionization (MALDI) imaging mass spectrometry (IMS) for　CNS of murine model of MS; experimental autoimmune encephalomyelitis (EAE). We have successfully identified and visualized several proteins specifically expressed in lesions of EAE at preclinical to clinical stages. It was functionally validated on an EAE model with or without blocking agents of the proteins. Furthermore, in depth proteomics using LC-TIMS-MS/MS for the cells infiltrated into CNS was also performed. In understanding molecular mechanisms of disease progression as well as pharmacological effects of the agents above mentioned, we have utilized whole animal IMS at the proteomics level.